'Ppar' presentation slideshows

About OMICS Group

About OMICS Group.

607 views • 50 slides

PPAR ? activation drives Th17 cells into a Treg phenotype

PPAR ? activation drives Th17 cells into a Treg phenotype. The CD4+ T cell computational model June 2014, MMI Summer School. What will this presentation show you?. Refinement of the model with new generated data. In vivo/vitro validation Hypothesis testing. Modeling approach.

463 views • 31 slides

PPAR ? activation drives Th17 cells into a Treg phenotype

PPAR ? activation drives Th17 cells into a Treg phenotype. The CD4+ T cell computational model June 2014, MMI Summer School. What will this presentation show you?. Refinement of the model with new generated data. In vivo/vitro validation Hypothesis testing. Modeling approach.

703 views • 31 slides

Lipaglyn TM Discovery, Development & Preclinical Studies

554 views • 25 slides

Lipaglyn TM Discovery, Development & Preclinical Studies

620 views • 25 slides

New perspectives in the therapy with PPAR- ? agonists .

XIII International Symposium Heart Failure & Co. New perspectives in the therapy with PPAR- ? agonists. Carlo Maria Rotella, Ilaria Dicembrini. Napoli, 12-13 aprile 2013. Properties of PPAR- ?. PPAR- ? ligands. Adverse events associated with PPAR- ? agonists.

339 views • 16 slides

Regulation of Lipid Synthesis and Development of Meibomian Gland Dysfunction

Regulation of Lipid Synthesis and Development of Meibomian Gland Dysfunction. Dustin Buchanan Mentored by Mindy Call. Introduction.

268 views • 16 slides

Diabetes & Metabolic Health Research Group Centre for Biomedical Science,

Diabetes & Metabolic Health Research Group Centre for Biomedical Science, Cardiff School of Health Sciences. Diabetes & Metabolic Health Research Group. Inflammatory/cell-signaling aspects of diabetes-associated cardiovascular disease (CVD).

274 views • 12 slides

The Effect of Resveratrol on Fat Storage

The Effect of Resveratrol on Fat Storage. By Chris LoBello. Obesity. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps. Adipocytes. http://whyfiles.org/276metabolic_syndrome/index.php?g=3.txt. http://www.nature.com/nri/journal/v6/n10/images/nri1937-f1.jpg. PPAR g.

255 views • 11 slides

Appendix 1

A. B. mPPAR a. 18. hPPAR a. **. 20. **. **. **. **. **. 12. Relative reporter activity. 15. Relative reporter activity. 10. *. 6. *. 5. *. 0. (-). WY. Rosi. GW. CG269. 0. 1 m M 1 m M 1 m M. (-). WY. Rosi. GW. CG269. 1 m M 1 m M 1 m M. C. D. #. PPAR d.

256 views • 10 slides

PPARs (Peroxisome proliferator activated receptor)

PPARs (Peroxisome proliferator activated receptor). Jun- su Park. PPARs. AF1. DBD. Hinge. LBD AF2. N. C. A/B. C. D. E/F. Activation Function 1 Transactivation. Activation Function 2 Transactivation. DNA-binding domain. Ligand-binding domain. PPARs.

215 views • 10 slides

QSAR studies on bisaryl substituted thiazoles and oxazoles as PPARδ agonists

A linear quantitative structure-activity relationship (QSAR) model is presented for modeling and predicting the agonistic activity of PPARδ receptor. The model was produced by using the multiple linear regression (MLR) technique on a compound database that consists of newly discovered bisaryl substituted thiazoles and oxazoles. The major conclusion of this study is that molecular weight, wiener index, andrews affinity and polar surface area affect significantly the agonistic activity of PPARδ receptor by bisaryl substituted thiazoles and oxazoles. The selected QSAR descriptors serve as a primary guidance for the design of novel and selective PPARδ receptor agonists.

121 views • 10 slides

New perspectives in cardio protection: Focus on PPAR ? activation

New perspectives in cardio protection: Focus on PPAR ? activation. ? -Glucosidase inhibitors. Thiazolidinediones. Muscle and adipose tissue: ?insulin resistance ?glucose uptake. Intestine: ?glucose absorption. Blood glucose. Liver: ?hepatic glucose output ?glucose uptake.

84 views • 8 slides

100

Uno et al. Figure S 1. B. A. *. **. 1.5. 0.5. 0.4. 1.0. Body Weight Change (g). WAT Weight (g). LacZ. PPAR g 2. 0.3. 0.2. IB: PPAR g. 0.5. 0.1. 0. 0. C. D. E. *. *. **. 200. 1.5. 1.5. FBG (mg/dl). 150. AGT mRNA. 1.0. Renin mRNA. 1.0. 100. 0.5. 0.5. 50.

205 views • 7 slides

Caption N-terminal domain A/B domain : ligand-independent domain AF1: Activation F unction 1

Structural Organization of PPAR?. Caption N-terminal domain A/B domain : ligand-independent domain AF1: Activation F unction 1 DBD: DNA B inding D omain LBD: L igand B inding Domain: ligand - dependent domain AF2: Activation Function 2 C-terminal domain. Sumoylation.

287 views • 4 slides

DMSO

Ciglitazone. DMSO. 0 0.5 1 1.5 0 0.5 1 1.5 h. IRF-1. GAPDH. 1.2. DMSO. Ciglitazone. 1. 0.8. Relative IRF-1 mRNA Level. 0.6. 0.4. 0.2. 0. 0. 0.5. 1 hr. Time post actinomycin D treatment.

191 views • 2 slides

PPAR ? -RXR nuclear receptor complex and transcriptional activity (activation)

207 views • 2 slides

?????????? ? ??? ? ??????? -9 ????????????????

?????????? ? ??? ? ??????? -9 ????????????????.

115 views • 2 slides

JH Choi et al. Nature 466 , 451-456 (2010) doi:10.1038/nature09291

Anti-diabetic PPAR ? ligands block CDK5-mediated phosphorylation of PPAR ?. JH Choi et al. Nature 466 , 451-456 (2010) doi:10.1038/nature09291.

187 views • 1 slides

OPN

HD. HD. SDS. SDS. ALKP. 3. 200. 150. 2. 100. 1. 50. 0. 0. LEP. LPL. 150. 100. 150. 80. 100. 100. 60. 40. 50. 50. 20. 0. 0. 0. OCN. A. OPN. 200. 150. 100. 50. 0. B. PPAR- g. Supplementary Figure 1.

181 views • 1 slides